This activity will include Surv.AI Says™, an interactive, artificial intelligence-driven polling component.
Program Description
Every year in the United States, over 80 million people are prescribed medication for acute pain. Without adequate understanding of pain assessments, pain conditions, or their treatments, these patients may continue to experience diminished quality of life or chronic pain. Initiating therapies that address the underlying pathophysiology of pain can lead to improved pain control and avoid risks associated with conventional therapies, such as addiction with opioids. Emerging therapies for pain management focus on novel targets within the pain signaling pathways to provide effective pain relief with fewer adverse effects, but these multimodal, non-opioid therapies are often underused. In this program, expert panelists will share perspectives on pharmacists’ involvement in medication reconciliation and the management of acute pain, considering top challenges regarding treatment modalities.
Target audience: Community pharmacists, health-system pharmacists, managed care pharmacists, retail pharmacists, specialty pharmacists
Type of activity: Application
Release date: December 11, 2024
Expiration date: December 11, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the impact of acute pain and current challenges in its assessment and management
- Analyze the efficacy and safety of emerging non-opioid treatments in acute pain management
- Integrate evidence-based assessment tools and personalized treatment solutions to the care of patients with acute pain
Jeff Gudin, MD
Faculty
Department of Anesthesiology, Perioperative Medicine and Pain Management
The University of Miami Miller School of Medicine
Miami, Florida
Todd Brothers, PharmD, BCCCP, BCPS
Clinical Associate Professor of Pharmacy Practice
University of Rhode Island College of Pharmacy
Loredana Diana Ardeljan, PharmD, BCPS
Opioid Stewardship Pharmacist
Department of Pharmacy & Clinical Support
Dana-Farber Cancer Institute
Boston, Massachusetts
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-347-H08-P. The activity is available for CE credit through December 11, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Jeff Gudin, MD has the following financial relationships with commercial interests to disclose:
Consultant: Acertis Pharmaceuticals; Collegium Pharmaceutical; Hisamitsu Pharmaceutical Co, Inc; Sanofi; Tris Pharma, Inc
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Todd Brothers, PharmD, BCCCP, BCPS
Loredana Diana Ardeljan, PharmD, BCPS
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here